Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease

Autor: Yusuf Yilmaz, Cuma Bulent Gul, Mahmut Arabul, Ozlen Atug, Engin Ulukaya, Enver Dolar, Ozen Oz Gul, Arzu Yilmaztepe Oral, Sibel Aker
Přispěvatelé: Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı., Ulukaya, Engin, Gül, Özen Öz, Arabul, Mahmut, Gül, Cuma Bülent, Oral, Arzu Yılmaztepe, Aker, Sibel, Dolar, Mahmut Enver, A-7063-2018, AAI-1005-2021, AAG-9177-2021, A-5841-2017, K-5792-2018
Rok vydání: 2009
Předmět:
Male
Nonalcoholic steatohepatitis
Receptors
immunologic
Receptor for Advanced Glycation End Products
Enzyme linked immunosorbent assay
Nonalcoholic fatty liver
Clinical Biochemistry
Pathogenesis
Nonalcoholic fatty liver disease
Galectin-3
Protein blood level
Middle aged
Receptor
Priority journal
Biological markers
Fatty liver
General Medicine
Liver biopsy
Advanced glycation end product receptor
Alanine aminotransferase blood level
Female
Human
Adult
medicine.medical_specialty
Serum-levels
Major clinical study
digestive system
Rage
Article
Disease association
Enzyme-linked immunosorbent assay
Internal medicine
medicine
Humans
In patient
Receptor for advanced glycation endproducts (RAGE)
Human tissue
Form
business.industry
Protein
Insulin resistance
Plasma levels
Insulin-resistance
medicine.disease
End-products ages
digestive system diseases
Advanced Glycation Endproducts
Endocrinology
Alanine aminotransferase
Metabolic syndrome
Medical laboratory technology
business
Controlled study
Advanced Glycation End Product Receptor
6 N Carboxymethyllysine
Glycation
Zdroj: Clinical Biochemistry. 42:802-807
ISSN: 0009-9120
DOI: 10.1016/j.clinbiochem.2009.02.003
Popis: Objectives Levels of soluble receptor for advanced glycation endproducts (sRAGE) have been linked to several components of the metabolic syndrome. We tested the hypothesis that plasma levels of sRAGE may be associated with non-alcoholic fatty liver disease. Design and methods We enrolled subjects with definite nonalcoholic steatohepatitis (NASH, n = 40), borderline NASH (n = 8), simple fatty liver (n = 9) and healthy controls (n = 14). Plasma levels of sRAGE were measured by ELISA. Results Concentrations of sRAGE were significantly lower in patients with definite NASH (1080 ± 392 pg/mL, P
Databáze: OpenAIRE
Externí odkaz: